Soracom Announces Global Collaboration with Sony Semiconductor Solutions' SPRESENSE™ IoT Microcontrollers
Soracom, Inc., a global provider of advanced IoT connectivity, today announced that SPRESENSE™ from Sony Semiconductor Solutions Corporation (hereafter “SSS”) has joined the Soracom Partner Space ecosystem and SSS identified Soracom as a recommended provider of connectivity for its SPRESENSE microcontrollers.
SSS’s SPRESENSE 6-core microcontroller board is ideal for professional IoT use cases, with a streamlined form factor, ultra-low power consumption, multiple sensor inputs, internal GPS, and edge AI support. The unique combination of solid computing performance and advanced power efficiency makes SPRESENSE suitable for edge computing. SPRESENSE is featured in applications where there is a need for sensor analysis, machine learning, image processing and data filtering in which other microcontroller-based alternatives fall short.
SSS’s SPRESENSE LTE extension board offers an on-board antenna for global LTE Cat-M1 connectivity. Combined with Soracom’s global IoT connectivity, SSS’s SPRESENSE LTE extension board makes it easy to connect almost anywhere in the world, control connections through the Soracom console and API, and access a wide range of services supporting secure private networking, data and protocol management, and integration with leading cloud platforms.
"Collaboration with Soracom enables global connectivity to our IoT SPRESENSE solution, providing an out-of-the-box experience that ensures our customers can be dedicated to driving innovative IoT solutions, especially for Edge AI applications," said Kenichi Nakano, General Manager, Sony Semiconductor Solutions Corporation.
Supporting more than 4 million connections with global IoT coverage in more than 160 countries, Soracom offers a portfolio of powerful connectivity solutions that help IoT deployments connect securely and easily to leading hyperscaler platforms, reduce data and power requirements, and manage total cost of ownership at scale.
The Soracom Partner Space enables partners to access live opportunities and technical collaborations to provide services to IoT innovators around the world. In turn, customers are able to find trusted partners who will help them bring solutions to market and scale more quickly, create differentiators, and simplify the IoT journey. Soracom Partner Space partners have supported many of the projects behind Soracom’s expansion.
Soracom now offers the SPRESENSE LTE-M IoT Connectivity Kit in its online store. The package also includes the official LTE Extension board for SPRESENSE, a Soracom IoT SIM card, and access to Soracom connectivity and platform services.
“Soracom is committed to partnering with leaders in hardware, software, and services to offer customers a robust global ecosystem that accelerates speed to market and success at scale,” said Kenta Yasukawa, co-founder and CTO, Soracom. “Sony’s SPRESENSE offers IoT innovators an exceptional platform for creation of new connected experiences that take full advantage of edge and the cloud.”
For more information on the SPRESENSE LTE-M IoT Connectivity Kit or to purchase, visit the Soracom store or the SPRESENSEwebpage.
SPRESENSE™ is a trademark of Sony Group Corporation.
About SPRESENSE™
SPRESENSE is a low-power board computer for the IoT that is equipped with a GPS receiver and supports High-Resolution Audio codecs. The board allows for IoT versatility and can be developed for a vast range of uses, such as a drone utilizing the GPS and high-performance processor, a smart speaker utilizing High-Resolution Audio recording and playback as well as the built-in full-digital amplifier, or a low-power time-lapse camera utilizing the camera interface. SPRESENSE will make the IoT smarter and more efficient.
About Soracom
Soracom is leading the democratization of IoT connectivity, offering robust solutions specifically designed to make it easy to build, operate, and scale IoT deployments. Founded in 2015, Soracom now serves more than 20,000 startups, SMBs and global enterprises across all industries, from agriculture, energy, construction and transportation to consumer electronics, manufacturing, real estate and healthcare. Customers trust Soracom for affordable, reliable connectivity that accelerates speed to market, makes it easy to connect to the cloud, and offers access to a worldwide partner ecosystem. More information is available at www.soracom.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005281/en/
Contact information
Justine Schneider
Calysto Communications
jschneider@calysto.com
O: 404-266-2060, ext. 507
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new